Ginkgo Bioworks Holdings, Inc. (DNA)

From the record

Ginkgo Bioworks Holdings, Inc.'s filings since 2020 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2024-09-04); an auditor change (8-K item 4.01, 2 times, the latest 2024-03-14); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2023-03-01) (its current reports).

From the record

Ginkgo Bioworks Holdings, Inc.'s 7 filed years say what it did: revenue went from $54 million in fiscal 2019 to $170 million in fiscal 2025, up 21% a year; it rose in 3 of 6 years; the deepest fall was 64% from fiscal 2022 to fiscal 2025; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ginkgo Bioworks Holdings, Inc. lost about 61 cents for every dollar of shareholders' money. Leverage: it owed about 55 cents per dollar of assets, and net share issuance: its share count grew 6.9% over the year (the filed statements).

From the record

Ginkgo Bioworks Holdings, Inc.'s standing among 102 graded names in its industry family: revenue of $170 million in fiscal 2025 ranks in the top 22% by size; a net margin of -183.8% ranks in the top 44%; revenue growth of -29.1% a year over the last 3 filed years ranks in the bottom 20% (its annual reports).

From the record

Ginkgo Bioworks Holdings, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 7 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 42%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 43%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ginkgo Bioworks Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $212 million against no long-term debt tagged leaves 19% of its assets as net cash, bottom 37% of its family; cash from operations less capital spending is -105% of revenue (top 39%); research spending of 143.3% of revenue (bottom 47%) (its annual report).

From the record

Ginkgo Bioworks Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -29.1% a year over the last three filed years against 21% over all 7, slowing (bottom 18% of its family); the newest year grew -25.1% (bottom 19%); research spending grew -38.6% a year (bottom 4%); capital spending grew -47.3% a year (bottom 32%) (its annual reports). Ginkgo Bioworks Holdings, Inc. reported 2 product lines in fiscal 2025: Cell Engineering Revenue at $133 million (78%), Service at $37 million (22%); 0 of 2 grew against the year before (its annual report).

From the record

Ginkgo Bioworks Holdings, Inc.'s newest year against its own record: revenue of $170 million in fiscal 2025 came in 8.7% above the $157 million its prior three years' pace pointed to (top 44% of its family); net income of $313 million against a prior three-year average of $1.2 billion (top 21%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 38%) (its annual reports).